Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omr-IgG-am for West Nile Virus Encephalitis/Myelitis
NCT00068055Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2003
- Primary completion
- Dec 2006
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Omr-IgG-am in West Nile virus infection (WNV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Safety (including all causes of mortality). Started Sep 2003; status: completed.
02
Drugs
Omr-IgG-am
03
Conditions
West Nile virus infection (WNV)
Beyond the preview
Go deeper on NCT00068055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00068055.